SCHEMBL4493858

SCHEMBL4493858

CC(C(=O)O)c1ccc2c(c1)C=CC(C)(C)O2

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 3/20 0.49
PTGS1 P23219 2/20 0.49
HIF1A Q16665 6/20 0.47
ALDH1A1 P00352 2/20 0.46
HPGD P15428 2/20 0.46
CYP3A4 P08684 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
EPAS1 Q99814 5/20 0.46
PTPN1 P18031 1/20 0.43
COXFA4 O00483 1/20 0.41
KDM4E B2RXH2 1/20 0.41
NPC1 O15118 1/20 0.41
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
TP53 P04637 1/20 0.41
POLB P06746 1/20 0.41
MAPT P10636 1/20 0.41
CA7 P43166 1/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10962863 0.85 HIF1A (0.50) PTGS2PTGS1HIF1AALDH1A1HPGD
SCHEMBL9582367 0.82 HIF1A (0.45) PTGS2PTGS1HIF1AALDH1A1HPGD
SCHEMBL5304916 0.77 HIF1A (0.46) PTGS2PTGS1HIF1AALDH1A1HPGD
SCHEMBL30874660 0.76 COXFA4 (0.53) PTGS2PTGS1HIF1AALDH1A1HPGD
SCHEMBL8066269 0.76 COXFA4 (0.53) PTGS2PTGS1HIF1AALDH1A1HPGD
SCHEMBL9405208 0.75 AKR1C3 (0.39) PTGS2PTGS1HIF1AALDH1A1HPGD
SCHEMBL10963991 0.75 PTGS1 (0.36) PTGS2PTGS1ALDH1A1HPGDCYP3A4
SCHEMBL16694313 0.75 HIF1A (0.67) HIF1AEPAS1COXFA4
SCHEMBL16694230 0.75 HIF1A (0.67) HIF1AEPAS1COXFA4
SCHEMBL16694229 0.75 HIF1A (0.67) HIF1AEPAS1COXFA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7534903-B2 Use of amidomethyl-substituted 2-(4-sulfonylamino)-3-hydroxy-3,4-dihydro-2H-chromen-6-yl-compounds in the treatment of cardiac arrhythmia and other disease states SOLVAY PHARMACEUTICALS GMBH (DE) 2009-05-19 US disclosed
EP-1678130-B1 AMIDOMETHYL-SUBSTITUTED 2-(4-SULFONILAMINO)-3-HIDROXY-3,4-DIHYDRO-2H-CHROMIUM-6-YL-DERIVATIVES AND DRUGS CONTAINING SAID COMPOUNDS SOLVAY PHARM GMBH (DE) 2008-08-20 EP disclosed
US-20080113999-A1 Use of Amidomethyl-Substituted 2-(4-Sulfonylamino)-3-Hydroxy-3,4-Dihydro-2H-Chromen-6-yl-Compounds in the Treatment of Cardiac Arrhythmia and Other Disease States SOLVAY PHARMACEUTICALS GMBH (DE) 2008-05-15 US disclosed
US-7368582-B2 Amidomethyl-substituted 2-(4-sulfonylamino)-3-hydroxy-3,4-dihydro-2H-chromen-6-yl compounds, a process and intermediates for their production, and pharmaceutical compositions containing them SOLVAY PHARMACEUTICALS GMBH (DE) 2008-05-06 US disclosed
EP-1678130-A2 AMIDOMETHYL-SUBSTITUTED 2-(4-SULFONILAMINO)-3-HIDROXY-3,4-DIHYDRO-2H-CHROMIUM-6-YL-DERIVATIVES AND DRUGS CONTAINING SAID COMPOUNDS Solvay Pharmaceuticals GmbH (DE) 2006-07-12 EP disclosed
US-20050148659-A1 Amidomethyl-substituted 2-(4-sulfonylamino)-3-hydroxy-3,4-dihydro-2H-chromen-6-yl compounds, a process and intermediates for their production, and pharmaceutical compositions containing them SOLVAY PHARMACEUTICALS GMBH (DE) 2005-07-07 US disclosed
WO-2005037780-A2 AMIDOMETHYL-SUBSTITUTED 2-(4-SULFONILAMINO)-3-HIDROXY-3,4-DIHYDRO-2H-CHROMIUM-6-YL-DERIVATIVES AND DRUGS CONTAINING SAID COMPOUNDS SOLVAY PHARMACEUTICALS GMBH (DE) 2005-04-28 WO disclosed
EP-0074170-B1 CHROMAN COMPOUNDS, PROCESS FOR PRODUCING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM NIPPON ZOKI PHARMACEUTICAL CO. LTD. (JP) 1985-10-16 EP disclosed
US-4545993-A ANTINFLAMMATORY AGENTS, ANTIPYRETICS, ANALGESICS NIPPON ZOKI PHARMACEUTICAL CO. LTD. (JP) 1985-10-08 US disclosed
EP-0074170-A1 Chroman compounds, process for producing them and pharmaceutical compositions containing them NIPPON ZOKI PHARMACEUTICAL CO. LTD. (JP) 1983-03-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050148659-A1 Amidomethyl-substituted 2-(4-sulfonylamino)-3-hydroxy-3,4-dihydro-2H-chromen-6-yl compounds, a process and intermediates for their production, and pharmaceutical compositions containing them H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP4B1, CYP3A4 PTGS2 1549/4885PTGS1 2100/4885HIF1A 2727/4885
US-20080113999-A1 Use of Amidomethyl-Substituted 2-(4-Sulfonylamino)-3-Hydroxy-3,4-Dihydro-2H-Chromen-6-yl-Compounds in the Treatment of Cardiac Arrhythmia and Other Disease States KCNH1, RYR2, KCNJ2 PTGS2 2460/4885PTGS1 2632/4885HIF1A 2348/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.